These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2669067)

  • 1. Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients.
    Cleton FJ; van Holten-Verzantvoort AT; Bijvoet OL
    Recent Results Cancer Res; 1989; 116():73-8. PubMed ID: 2669067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
    van Holten-Verzantvoort AT; Bijvoet OL; Cleton FJ; Hermans J; Kroon HM; Harinck HI; Vermey P; Elte JW; Neijt JP; Beex LV
    Lancet; 1987 Oct; 2(8566):983-5. PubMed ID: 2889957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia.
    Stevens MJ
    Med J Aust; 1987 Mar; 146(5):261-4. PubMed ID: 3821622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bisphosphonates and bone metastases].
    Lortholary A; Jadaud E; Berthaud P
    Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma.
    Harvey HA
    Cancer; 1997 Oct; 80(8 Suppl):1646-51. PubMed ID: 9362431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and breast carcinoma.
    Lipton A
    Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of Clodronate in the treatment of bone metastasis].
    Pouillart P; Beuzeboc P
    Bull Cancer; 1991; 78(8):737-41. PubMed ID: 1834287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
    Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
    J Clin Oncol; 1993 Jan; 11(1):59-65. PubMed ID: 8418243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone.
    Biermann WA; Cantor RI; Fellin FM; Jakobowski J; Hopkins L; Newbold RC
    Bone; 1991; 12 Suppl 1():S37-42. PubMed ID: 1720013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates: biological response modifiers in breast cancer.
    Paterson AH
    Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
    Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
    Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of skeletal disease in breast cancer with clodronate.
    Paterson AH; Ernst DS; Powles TJ; Ashley S; McCloskey EV; Kanis JA
    Bone; 1991; 12 Suppl 1():S25-30. PubMed ID: 1720012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.